Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MAR001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Sofinnova Investments
Deal Size : $190.0 million
Deal Type : Series B Financing
Marea Therapeutics Launches with $190M to Develop Medicines for Cardiometabolic Diseases
Details : The financing aims to fund the company’s lead product, MAR001, a monoclonal antibody targets ANGPTL4. Currently, it is being evaluated in early-stage trials for the treatment of hypertriglyceridemia.
Brand Name : MAR001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : MAR001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Sofinnova Investments
Deal Size : $190.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?
Reset All
